Day 1: Wednesday, 23 October 2019 (09:00-17:30)
09.00-09.45: Welcome
- Minister of Labour, Social Affairs, Health and Consumer Protection Brigitte Zarfl
- Executive Director Herwig Ostermann, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute)
- Andrew Rintoul, Access to Medicines, Vaccines and Pharmaceuticals, World Health Organization Headquarters
- Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Sabine Vogler (GÖG / Austrian National Public Health Institute)
09.45-10.30: Key Note: Global Access to Medicines Challenge. Time for a new approach?
Ellen ‘t Hoen, Medicines Law & Policy, The Netherlands Download
10.30-11.00 Coffee Break
11.00-12.15: Stakeholder Roundtable: Medicines access challenge – the value of pricing and reimbursement policies
Panelists
- Gaelle Krikorian, Médecins Sans Frontières (MSF)
- Marcel van Raaij, Dutch Ministry of Health, Welfare and Sports
- Andrew Rintoul, World Health Organization Headquarters
- Florian Turk, Sandoz Biopharmaceuticals, Germany
Facilitator: Hans Hogerzeil, University Groningen, The Netherlands
12.15–12.30: Outlook on Conference
12.30-14.00: Lunch Break
14.00–15.00 Breakout Session (Strand I – Strand III)
Strand I: Local challenges, global learnings?
- Key Note: Veronika Wirtz, Boston University, USA Download
- Differences in health technology assessment recommendations between European jurisdictions: the role of practice variations (Rick A Vreman, Utrecht University, The Netherlands) Download
- Relationship between pricing regulations and medicine prices: A multi-jurisdictional comparative analysis of real price indices for pharmaceuticals, 1981-2017 (Kiu Tay-Teo, World Health Organization)
Facilitator: Zaheer-Ud-Din Babar, University of Huddersfield, United Kingdom
Strand II: ‘Fake’ prices – Are price surveys still useful?
- Key Note: Dimitra Panteli, TU Berlin, Germany Download
- Impact of managed-entry agreements on medicines list prices (Paolo Pertile, University of Verona, Italy) Download
- European price comparison for patented drugs (Melanie Schröder, WIdO - AOK Research Institute, Germany) Download
Facilitator: Claudia Habl, GÖG / Austrian National Public Health Institute
Strand III: Fix the future?
- Key Note: Valerie Paris, OECD Download
- Ten-year impact of the Access to Medicines Index: Changes in industry pricing and intellectual property policies in Low and Middle Income Countries from 2008-2018 (Hans V Hogerzeil, Access to Medicine Foundation, The Netherlands) Download
- Robust 5-year-forecast of the Austrian reimbursable pharmaceutical retail market (Karin Komposch, IQVIA, Austria) Download
Facilitator: Aukje Mantel-Teeuwisse, WHO Collaborating Centre of Pharmaceutical Policy and Regulation, Utrecht University, The Netherlands
15.00–15.30: Poster walk during the coffee break
15.30 –16.30 Moderated Poster Session
Strand I: Local challenges, global learnings?
- A comprehensive framework of pharmaceutical policies for decision-makers: functions, tools and data requirements (Ioana Ursu, Mapping Health Limited, UK) Download
- Drug Governance in the Emilia-Romagna Region, Italy (Francesco Nonino, Direzione Generale Cura della Persona Salute e Welfare, Servizio Assistenza Territoriale, Area Farmaco e Dispositivi Medici, Regione Emilia Romagna, Italy) Download
- Mechanism for introduction of outpatient medicine in the reimbursement list in R. Moldova: development and challenges (Rita Seicas, Center PAS, Republic of Moldova) Download
- Case study of the judicialisation of eculizumab (Soliris): challenges in the price regulation and the impact of establishment of the maximum government price in Brazil (Adriana Mitsue Ivama Brummell, Brazilian Health Regulatory Agency (Anvisa)) Download
Facilitator: Jaime Espin Balbino, Andalusian School of Public Health (EASP), Spain
Strand II: ‘Fake’ prices – Are price surveys still useful?
- How the Euripid Collaboration contributes to the affordability of medicines in Europe (Claudia Habl, Austrian National Public Health Institute) Download
- Ex-Post analysis of medicines subject to Managed-Entry-Agreements (MEAs) – a feasible approach for monitoring and price analyses (Peter Schneider, Austrian National Public Health Institute) Download
- Impact of the external price referencing methodology (EPR) on medicine prices – Simulation of existing EPR models (Sabine Vogler, Austrian National Public Health Institute) Download
- Estimating price developments of biological medicines during market exclusivity (Peter Schneider, Austrian National Public Health Institute) Download
Facilitator: Dimitra Panteli, TU Berlin, Germany
Strand III: Fix the future?
- Monitoring evidence on overall survival benefits of anti-cancer drugs approved by the European Medicines Agency between 2009 and 2015 (Nicole Grössmann, Ludwig Boltzmann Institute for Health Technology Assessment, Austria) Download
- Innovative policy options to secure access to medicines – a literature review (Nora Franzen, The Netherlands Cancer Institute) Download
- Integrating public preferences into reimbursement decisions: case studies from Belgium and New Zealand (Christine Leopold, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA) Download
- Joint Procurements - Learnings from a pilot of procuring medicine jointly (Trine Ann Behnk, AMGROS, Denmark) Download
Facilitator: Fatima Suleman, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, South Africa
16.30-17.30: Reception
Day 2: Thursday 24 October 2019 (09:00 - 16:30)
08.00-08.45: Early Bird Session: Meet the editors of Journals in the pharmaceutical field
- Adis HEOR Journals (Applied Health Economics and Health Policy, Pharmacoeconomics, Pharmacoeconomics - Open), Tim Wrightson Download
- Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar Download
- International Journal of Technology Assessment in Health Care, Claudia Wild Download
- Health Policy Journal, Dimitra Panteli
Facilitator: Aukje Mantel-Teeuwisse, Utrecht University, The Netherlands
09.00-09.30: Key Note: WHO and Access to medicines- an update.
Sarah Garner, WHO Regional Office for Europe Download
Facilitator: Valerie Paris, OECD, France
9.30-10.30: Country Poster Presentations
- European Union (Facilitator: Aldo Golja, Ministry of Health, Welfare and Sports, The Netherlands)
- Other European countries (Facilitator: Sarah Garner, WHO Regional Office for Europe, Denmark)
- Norway (Carolin Hagen, Ministry of Health and Care Services and Cathrine Kristiansen, Norwegian Medicines Agency) Download
- Republic of Moldova (Veaceslav Neagu, Medicines and Medical Devices Agency and Elena Chitan, State University of Medicine and Pharmacy "Nicolae Testemitanu") Download
- Ukraine (Oleksandr Komarida, Ministry of Health) Download
- Turkey (Enver Kagan Atikeler, Turkish Medicines and Medical Devices Agency and Canan Demir, Social Security Institution) Download
- Non-European countries (Andrew Rintoul, WHO Headquarters)
- Brazil (Adriana Mitsue Ivama Brummell, Brazilian Health Regulatory Agency (Anvisa) Download
- Canada (Guillaume Couillard and Jeffrey Menzies, Patented Medicine Prices Review Board) Download
- South Africa (Fatima Suleman, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal) Download
10.30–11.00: Country Poster walk during the coffee break
11.00–12.30 Breakout Session (Strand I – III)
Strand 1: Local challenges, global learnings?
- Key Note: Jaime Espin Balbino, Andalusian School of Public Health (EASP), Spain Download
- Biosimilars in Canada: current environment and future opportunity (Jeffrey Menzies, Patented Medicine Prices Review Board, Canada) Download
- An exploratory study into the use and pricing of schedule zero medicines post exemption from the Single Exit Price policy in South Africa. (Fatima Suleman, University of KwaZulu-Natal, South Africa) Download
- Promoting access to cancer medicines in Mexico: Seguro Popular key policy components. (Daniela Moye-Holz, University of Groningen, the Netherlands and Mexico) Download
Facilitator: Zaheer-Ud-Din Babar, University of Huddersfield, United Kingdom
Strand 2: ‘Fake’ prices – Are price surveys still useful?
- Key Note: Inneke Van de Vijver, INAMI, Belgium Download
- Influence of the difference in discounted price between biosimilar and originator product on competition in Sweden’s infliximab and etanercept market (Evelien Moorkens, KU Leuven, Belgium) Download
- Oncology drug market: a high-growth, high-price therapeutic area (Guillaume Couillard, Patented Medicine Prices Review Board, Canada) Download
- Public and philanthropic financial contributions to the development of new active substances: a bibliographic analysis (Claudia Wild, Ludwig Boltzmann Institute for Health Technology Assessment, Austria) Download
Facilitator: Christine Leopold, Consultant, Austria
Strand 3: Fix the future?
- Key Note: The need for better HTA methodology for more complex and personalised medicine (Wim Goettsch, Utrecht University, The Netherlands) Download
- Challenges of benefit assessment and reimbursement of new high-priced medicines – an analysis of regulatory framework and case studies from Germany (Anja Tebinka-Olbrich, GKV Spitzenverband, Germany)
- Together Working to Improve Access to Medicines: Analysis of Cross-country Collaborations in Europe (Rianne van den Ham, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, the Netherlands) Download
- Supporting Decision-Making on Costly Hospital Drugs in Austria: Approaches for Democratic Processes (Sarah Wolf, Ludwig Boltzmann Institute for Health Technology Assessment) Download
Facilitator: Veronika Wirtz, Boston University, USA
12.30–14.00: Lunch
14.00-15.00: Key Note: Fair pricing in theory and practice: transparency, governance and political will
Suerie Moon, Graduate Institute Geneva, Switzerland Download
15.00-15.30 Closing Commentary, conclusions, awards and closure
Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, GÖG/Austrian National Public Health Institute